ClinicaliQ Trial Snapshot
- ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP) — Recruiting • Gastroenterology • NCT04883905.
- What is being tested: ELEVATE is a global registry documenting the natural disease progression of acute hepatic porphyria (AHP) and evaluating real-world safety and effectiveness of givosiran alongside other approved AHP treatments.
- Patient eligibility overview: The registry enrolls patients with confirmed diagnoses of acute hepatic porphyria (including acute intermittent porphyria, variegate porphyria, and hereditary coproporphyria) across diverse clinical settings globally.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.
Eligibility Snapshot
- : * Documented diagnosis of AHP, per physician's determination
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.